The court observed that the development of such a vaccine for 'immuno-contraception' which would use an animal's immune response to prevent pregnancy was at an initial stage in India, adding that the process should be expedited.
A bench of Acting Chief Justice Gita Mittal and Justice C Hari Shankar said the vaccine was being used in other countries, and the possibility of developing an indigenous contraceptive vaccine was being considered.
"Why cannot we import this vaccine? We would like to know the possibility of it," it said.
Perusing the status report filed by the National Institute of Immunology (NII), the court said it showed that the development of the vaccine to control the population of animals, including monkeys, was still at the initial stage and the trial has not yet started.
"We are here to help you and this project. If you need anything, tell us. But it cannot be a 10 year programme," the bench observed.
The NII said in the report that once the vaccine candidates developed by the institute were validated, it will lead to development of indigenous contraceptive vaccine for population management of wildlife and thereby, mitigate the human-wildlife conflict.
The direction came after the Animal Welfare Board of India (AWBI) and Gauri Maulekhi, an animal rights activist, told the court that surgical sterilisation of animals, as was being considered by the Delhi government, would be "counter-productive".
They said surgical sterilisation would disrupt the social groups of animals, make them more ferocious and also leave a human imprint, all of which need to be avoided.
They had earlier said that several countries, including some in Africa, have developed and used such vaccines which are administered orally.
The court was hearing two PILs seeking directions to the authorities to take steps to deal with the menace of monkeys and dogs as well as protection of peacocks.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
